Developer docs
API playgroundTry for free, no card

Search company profiles

JW Therapeutics

Full company profile

uuid0000n71

Namestring
JW Therapeutics
Legal namestring
JW Therapeutics (Shanghai) Co., Ltd. (上海药明巨诺生物科技有限公司)
Company typeenum
Public
Founded yearint
2016
Descriptiontext

JW Therapeutics (药明巨诺, HKEx: 2126) is a Shanghai-based, publicly traded clinical-stage and commercial-stage biopharmaceutical company founded in 2016 as a joint venture between WuXi AppTec and Juno Therapeutics (now a Bristol Myers Squibb subsidiary, the company's largest shareholder). The company develops, manufactures, and commercializes cell immunotherapy products, principally autologous anti-CD19 CAR-T therapies. Its lead commercial product is Carteyva (relmacabtagene autoleucel injection / relma-cel), which is China's first Category 1 biologics CAR-T approval and is currently marketed for three relapsed/refractory B-cell non-Hodgkin lymphoma indications (r/r LBCL, r/r FL, and r/r MCL), with Macau approval secured in June 2025.

The company's core technology stack comprises (i) a CAR-T platform with proprietary CD19/CD20 dual-targeting (JWCAR201) and armored, persistence-enhanced constructs (JWCAR239); (ii) a self-developed lentiviral vector production system (sLVV / JWLV011) intended to replace imported vectors and reduce per-batch cost; (iii) a 19-node COI/COC traceability system integrated with MES, SAP, and LIMS for real-time GMP quality monitoring; and (iv) a manufacturing footprint anchored by a ~12,000 sqm Suzhou commercial facility designed for up to 3,000 autologous batches per year, plus a ~2,500 sqm Zhangjiang R&D center in Shanghai. Beyond hematologic oncology, the pipeline targets solid tumors (MAGE-A4 TCR-T JWTCR001, GPC3 CAR-T JWATM204, JWATM214) and autoimmune diseases (SLE, systemic sclerosis) using relma-cel as a CD19 B-cell depletion platform.

Commercially, JW Therapeutics operates an enterprise field-sales model that distributes through a published, updatable network of trained and certified medical institutions authorized to administer Carteyva, with per-infusion pricing between CNY 999,000 and 1.3 million. Revenue is generated via (a) one-time product sales of Carteyva, supported by 100+ Inclusive Supplementary Health Insurance plans and inclusion (effective January 2026) in the national NHSA Commercial Health Insurance Innovative Drug Directory; and (b) technology licensing and milestone payments — including an sLVV license to Juno (up to USD 10 million) and an expanded TCR-T collaboration with Regeneron (up to USD 50 million in milestones), with JW retaining Greater China commercialization rights. Headcount is reported at 251-500, with operations concentrated in Shanghai, Suzhou, and Beijing.

Short descriptiontext

JW Therapeutics (药明巨诺, HKEx: 2126) is a Shanghai-headquartered, publicly traded cell immunotherapy company that develops, manufactures, and commercializes autologous CAR-T therapies, with Carteyva approved in China and Macau for three relapsed/refractory B-cell non-Hodgkin lymphoma indications and a broader pipeline in solid tumors and autoimmune diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR-T cell therapy, cell immunotherapy, autologous cell therapy, lentiviral vector manufacturing, oncology biologics
Industry3 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Immunotherapy (CAR-T)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CAR-T Product Sales (Carteyva/Bienaida)
TypeOne Time License
Description

Revenue from commercial sales of relmacabtagene autoleucel injection (Carteyva/倍诺达) for approved oncology indications including r/r LBCL, r/r FL, and r/r MCL, priced at CNY 999,000 to CNY 1.3 million per infusion

jwtherapeutics.com
2Technology Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from licensing proprietary CAR-T manufacturing processes (Drug Product Process, Lentiviral Vector Manufacturing Process) to global partners such as Regeneron, generating milestone payments up to USD 50 million and sLVV licensing fees up to USD 10 million from Juno Therapeutics

jwtherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales
Pricing details1 tier
1Standard CAR-T treatment pricing (Carteyva/倍诺达)
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Prices between CNY 999,000 and CNY 1.3 million per infusion. Therapy approved for three non-Hodgkin lymphoma indications: r/r LBCL, r/r FL, and r/r MCL.

yicaiglobal.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1倍诺达® (Carteyva®)
Description

Relmacabtagene autoleucel injection (relma-cel) - the company's first approved CAR-T product for hematologic malignancies including LBCL, FL, and MCL

jwtherapeutics.com
+2 more records
Core offering1 text field

JW Therapeutics develops, manufactures, and commercializes autologous CAR-T cell immunotherapy products. Its flagship product Carteyva (relmacabtagene autoleucel injection) is approved in China for three non-Hodgkin lymphoma indications (r/r LBCL, r/r FL, r/r MCL) and priced at CNY 999,000 to CNY 1.3 million per infusion. The company also licenses its proprietary manufacturing processes (including self-developed lentiviral vector technology) to global partners such as Juno Therapeutics/BMS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% SRI-4 response rate in SLE Phase 1 trial (12/12 patients)
+3 more records
Product overview1 text field

JW Therapeutics (港交所代码:2126) is an independent innovative biotechnology company founded in 2016 through a collaboration between WuXi AppTec and Juno Therapeutics, focusing on developing, manufacturing, and commercializing cell immunotherapy products. The company operates an integrated platform spanning scientific discovery, process development, manufacturing, quality management, and clinical application. The core product portfolio centers on CAR-T cell therapies led by Carteyva® (Relmacabtagene Autoleucel Injection / relma-cel), China's first Category 1 biologics CAR-T product approved for three non-Hodgkin lymphoma indications. The pipeline includes next-generation CAR-T products (JWCAR201, JWCAR239) with dual CD19/CD20 targeting and armored module technologies, BCMA-targeted JWCAR129, solid tumor programs (JWTCR001 for MAGE-A4 TCR-T, JWATM204, JWATM214), and autoimmune disease applications (SLE, SSc). Manufacturing infrastructure includes a Suzhou commercial production base with ~3,000 patient capacity annually and a Zhangjiang R&D center for process development. The company maintains global partnerships with Regeneron for TCR-T development and Juno Therapeutics/BMS for technology licensing.

Product and service9 records
1Carteyva® (Relmacabtagene Autoleucel Injection / Relma-cel)
CategoryCell Immunotherapy (CAR-T)
Description

Autologous anti-CD19 CAR-T cell immunotherapy product for adult patients with relapsed or refractory large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma; commercial pricing CNY 999,000 to CNY 1.3 million per infusion.

2JWCAR201
CategoryCell Immunotherapy (CAR-T)
Description

Autologous dual-targeting CD19/CD20 CAR-T product designed to prevent antigen escape and manufactured using a rapid, automated platform; in clinical trials for relapsed/refractory diffuse large B-cell lymphoma.

3JWCAR239
CategoryCell Immunotherapy (CAR-T)
Description

Enhanced autologous anti-CD19/CD20 dual-targeting CAR-T cell therapy incorporating armored modules designed to promote persistence, augment co-stimulation, and provide immune shielding, in clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma.

4JWCAR129 (BCMA-targeted CAR-T)
CategoryCell Immunotherapy (CAR-T)
Description

BCMA-targeted CAR-T cell therapy candidate based on Juno's orvacabtagene autoleucel (orva-cel) construct, in preclinical and clinical development for multiple myeloma.

5JWTCR001 (MAGE-A4 TCR-T 2.0)
CategoryCell Immunotherapy (TCR-T)
Description

Next-generation MAGE-A4 TCR-T cell therapy featuring CTBR12 switch receptor technology that converts TGF-β inhibition signals into activation signals, targeting solid tumors including esophageal squamous cell carcinoma, synovial sarcoma, ovarian cancer, and squamous NSCLC; in Phase I MARVEL trial in China.

6JWATM204 (GPC3-targeted CAR-T)
CategoryCell Immunotherapy (CAR-T)
Description

Autologous CAR-T product targeting GPC3 (glypican-3) for hepatocellular carcinoma and solid tumors, based on Eureka's CAR constructs, in a Phase I investigator-initiated trial in China.

7JWATM214
CategoryCell Immunotherapy (CAR-T)
Description

CAR-T product for solid tumors developed using Lyell technology, in preclinical and early clinical development.

8Relma-cel for Systemic Lupus Erythematosus (SLE)
CategoryCell Immunotherapy (Autoimmune)
Description

CD19 CAR-T therapy (relmacabtagene autoleucel) being developed for autoimmune indications including SLE and lupus nephritis; Phase 1 data showed a 100% SRI-4 response rate.

9Relma-cel for Systemic Sclerosis (SSc)
CategoryCell Immunotherapy (Autoimmune)
Description

CD19 CAR-T therapy (relmacabtagene autoleucel) for progressive diffuse cutaneous systemic sclerosis; Phase 1 trial demonstrated deep B-cell depletion and was presented at SSWC 2026 as a Late-Breaking abstract.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-28
Description

Collaboration to evaluate combination of Imugene's CF33-CD19 oncolytic virus (onCARlytics) with JW's Carteyva CD19 CAR-T therapy for refractory solid tumors. Includes preclinical studies and Phase 1 trial in China, developing novel 'mark and kill' treatment strategy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Expanded strategic collaboration for TCR-T cell therapy development. JW Therapeutics receives up to USD 50 million in milestone payments for MAGE-A4 product development. Regeneron grants non-exclusive global license to JW Therapeutics' Drug Product Process and option for Lentiviral Vector Manufacturing Process. JW Therapeutics retains Greater China development and commercialization rights.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Strategic alliance for MAGE-A4 TCR.CTBR12 (JWTCR001) development in China, Hong Kong, and Macau. JWTCR001 uses proprietary CTBR12 switch receptor technology to convert TGF-beta suppression into activation signal for enhanced antitumor activity in solid tumors.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-04-14
Description

sLVV (self-developed lentiviral vector) manufacturing technology licensing agreement. JW Therapeutics grants Juno non-exclusive license to JW sLVV manufacturing process for CAR-T production. Total consideration up to USD 10 million. Juno is BMS's CAR-T subsidiary and JW Therapeutics' largest shareholder.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

JW Therapeutics was co-founded in 2016 by WuXi AppTec and Juno Therapeutics, combining global cell therapy expertise with Chinese pharmaceutical development and manufacturing capabilities.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage gene and cell therapy company developing allogeneic CAR-T and TCR-T platforms; competes in JW's solid tumor and hematologic cell therapy development space across multiple modalities.

2Carsgen Therapeutics
TypeDirect peer
Description

Hong Kong-listed Chinese CAR-T developer of zevorcabtagene autoleucel (zev-cel, CT041), approved for multiple myeloma and operating in CAR-T cell therapy with overlapping hematologic malignancy indications.

TypeDirect peer
Description

Develops Carvykti, a BCMA-directed CAR-T co-developed with Johnson & Johnson for multiple myeloma - a direct BCMA-targeting CAR-T peer overlapping with JW's JWCAR129 pipeline asset.

TypeEmerging player
Description

US-listed allogeneic CAR-T developer whose off-the-shelf approach could disrupt the autologous CAR-T economics on which JW's Carteyva depends; competitor in the broader hematologic cell therapy market.

TypeEmerging player
Description

US/CN clinical-stage biotech developing solid-tumor CAR-T constructs (including GPC3 targeting) - JW's JWATM204 program is based on Eureka's CAR constructs, making Eureka a technology licensor and direct pipeline peer.

6Bristol Myers Squibb
TypeBroad incumbent
Description

Global CAR-T leader through its Juno Therapeutics subsidiary (Brexucabtagene Autoleucel / Breyanzi / Abecma) and JW Therapeutics' largest shareholder and technology-licensing partner - defines the competitive and governance landscape for JW.

TypeBroad incumbent
Description

Develops and commercializes Kymriah, the first FDA-approved CAR-T therapy; a global incumbent in the same CAR-T modality that JW Therapeutics targets, providing global competitive and regulatory benchmarks.

8Fosun Kite Biotechnology
TypeDirect peer
Description

Chinese JV between Fosun Pharma and Kite (Gilead) that localizes and commercializes Yescarta CAR-T therapy in China for B-cell NHL - directly competes with Carteyva in the same approved indications and hospital channel.

TypeBroad incumbent
Description

Markets Yescarta and Tecartus CAR-T therapies globally via its Kite subsidiary, including in China through the Fosun Kite JV - establishes the competitive CAR-T benchmark JW must beat on cost, manufacturing, and indication breadth.

TypeDirect peer
Description

Chinese allogeneic CAR-T developer acquired by AstraZeneca, focused on B-cell malignancies and autoimmune - directly competes in next-generation cell therapy formats targeting the same Chinese patient population.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JW Therapeutics

Cell Immunotherapy (CAR-T)jwtherapeutics.com

JW Therapeutics (药明巨诺, HKEx: 2126) is a Shanghai-headquartered, publicly traded cell immunotherapy company that develops, manufactures, and commercializes autologous CAR-T therapies, with Carteyva approved in China and Macau for three relapsed/refractory B-cell non-Hodgkin lymphoma indications and a broader pipeline in solid tumors and autoimmune diseases.

What JW Therapeutics does

JW Therapeutics (药明巨诺, HKEx: 2126) is a Shanghai-based, publicly traded clinical-stage and commercial-stage biopharmaceutical company founded in 2016 as a joint venture between WuXi AppTec and Juno Therapeutics (now a Bristol Myers Squibb subsidiary, the company's largest shareholder). The company develops, manufactures, and commercializes cell immunotherapy products, principally autologous anti-CD19 CAR-T therapies. Its lead commercial product is Carteyva (relmacabtagene autoleucel injection / relma-cel), which is China's first Category 1 biologics CAR-T approval and is currently marketed for three relapsed/refractory B-cell non-Hodgkin lymphoma indications (r/r LBCL, r/r FL, and r/r MCL), with Macau approval secured in June 2025.

The company's core technology stack comprises (i) a CAR-T platform with proprietary CD19/CD20 dual-targeting (JWCAR201) and armored, persistence-enhanced constructs (JWCAR239); (ii) a self-developed lentiviral vector production system (sLVV / JWLV011) intended to replace imported vectors and reduce per-batch cost; (iii) a 19-node COI/COC traceability system integrated with MES, SAP, and LIMS for real-time GMP quality monitoring; and (iv) a manufacturing footprint anchored by a ~12,000 sqm Suzhou commercial facility designed for up to 3,000 autologous batches per year, plus a ~2,500 sqm Zhangjiang R&D center in Shanghai. Beyond hematologic oncology, the pipeline targets solid tumors (MAGE-A4 TCR-T JWTCR001, GPC3 CAR-T JWATM204, JWATM214) and autoimmune diseases (SLE, systemic sclerosis) using relma-cel as a CD19 B-cell depletion platform.

Commercially, JW Therapeutics operates an enterprise field-sales model that distributes through a published, updatable network of trained and certified medical institutions authorized to administer Carteyva, with per-infusion pricing between CNY 999,000 and 1.3 million. Revenue is generated via (a) one-time product sales of Carteyva, supported by 100+ Inclusive Supplementary Health Insurance plans and inclusion (effective January 2026) in the national NHSA Commercial Health Insurance Innovative Drug Directory; and (b) technology licensing and milestone payments — including an sLVV license to Juno (up to USD 10 million) and an expanded TCR-T collaboration with Regeneron (up to USD 50 million in milestones), with JW retaining Greater China commercialization rights. Headcount is reported at 251-500, with operations concentrated in Shanghai, Suzhou, and Beijing.

JW Therapeutics firmographics

Firmographics
Name
JW Therapeutics
Legal name
JW Therapeutics (Shanghai) Co., Ltd. (上海药明巨诺生物科技有限公司)
Website
https://jwtherapeutics.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
JW Therapeutics (药明巨诺, HKEx: 2126) is a Shanghai-headquartered, publicly traded cell immunotherapy company that develops, manufactures, and commercializes autologous CAR-T therapies, with Carteyva approved in China and Macau for three relapsed/refractory B-cell non-Hodgkin lymphoma indications and a broader pipeline in solid tumors and autoimmune diseases.
Ownership category
akta.pro rank

JW Therapeutics industry classification

Industry
Product category
Cell Immunotherapy (CAR-T)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • CAR-T cell therapy
  • Cell immunotherapy
  • Autologous cell therapy
  • Lentiviral vector manufacturing
  • Oncology biologics

Where JW Therapeutics is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

JW Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

  1. CAR-T Product Sales (Carteyva/Bienaida): Revenue from commercial sales of relmacabtagene autoleucel injection (Carteyva/倍诺达) for approved oncology indications including r/r LBCL, r/r FL, and r/r MCL, priced at CNY 999,000 to CNY 1.3 million per infusion
  2. Technology Licensing and Milestone Payments: Revenue from licensing proprietary CAR-T manufacturing processes (Drug Product Process, Lentiviral Vector Manufacturing Process) to global partners such as Regeneron, generating milestone payments up to USD 50 million and sLVV licensing fees up to USD 10 million from Juno Therapeutics

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractStandard CAR-T treatment pricing (Carteyva/倍诺达)

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

JW Therapeutics product offering

Product offering

Core offering

JW Therapeutics develops, manufactures, and commercializes autologous CAR-T cell immunotherapy products. Its flagship product Carteyva (relmacabtagene autoleucel injection) is approved in China for three non-Hodgkin lymphoma indications (r/r LBCL, r/r FL, r/r MCL) and priced at CNY 999,000 to CNY 1.3 million per infusion. The company also licenses its proprietary manufacturing processes (including self-developed lentiviral vector technology) to global partners such as Juno Therapeutics/BMS.

Product overview

JW Therapeutics (港交所代码:2126) is an independent innovative biotechnology company founded in 2016 through a collaboration between WuXi AppTec and Juno Therapeutics, focusing on developing, manufacturing, and commercializing cell immunotherapy products. The company operates an integrated platform spanning scientific discovery, process development, manufacturing, quality management, and clinical application. The core product portfolio centers on CAR-T cell therapies led by Carteyva® (Relmacabtagene Autoleucel Injection / relma-cel), China's first Category 1 biologics CAR-T product approved for three non-Hodgkin lymphoma indications. The pipeline includes next-generation CAR-T products (JWCAR201, JWCAR239) with dual CD19/CD20 targeting and armored module technologies, BCMA-targeted JWCAR129, solid tumor programs (JWTCR001 for MAGE-A4 TCR-T, JWATM204, JWATM214), and autoimmune disease applications (SLE, SSc). Manufacturing infrastructure includes a Suzhou commercial production base with ~3,000 patient capacity annually and a Zhangjiang R&D center for process development. The company maintains global partnerships with Regeneron for TCR-T development and Juno Therapeutics/BMS for technology licensing.

Differentiator

Problem solved

Functional benefit

Brands

  • 倍诺达® (Carteyva®): Relmacabtagene autoleucel injection (relma-cel) - the company's first approved CAR-T product for hematologic malignancies including LBCL, FL, and MCL
  • onCARlytics
  • COI/COC System

Products and services

  • Carteyva® (Relmacabtagene Autoleucel Injection / Relma-cel) Autologous anti-CD19 CAR-T cell immunotherapy product for adult patients with relapsed or refractory large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma; commercial pricing CNY 999,000 to CNY 1.3 million per infusion.
  • JWCAR201 Autologous dual-targeting CD19/CD20 CAR-T product designed to prevent antigen escape and manufactured using a rapid, automated platform; in clinical trials for relapsed/refractory diffuse large B-cell lymphoma.
  • JWCAR239 Enhanced autologous anti-CD19/CD20 dual-targeting CAR-T cell therapy incorporating armored modules designed to promote persistence, augment co-stimulation, and provide immune shielding, in clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma.
  • JWCAR129 (BCMA-targeted CAR-T) BCMA-targeted CAR-T cell therapy candidate based on Juno's orvacabtagene autoleucel (orva-cel) construct, in preclinical and clinical development for multiple myeloma.
  • JWTCR001 (MAGE-A4 TCR-T 2.0) Next-generation MAGE-A4 TCR-T cell therapy featuring CTBR12 switch receptor technology that converts TGF-β inhibition signals into activation signals, targeting solid tumors including esophageal squamous cell carcinoma, synovial sarcoma, ovarian cancer, and squamous NSCLC; in Phase I MARVEL trial in China.
  • JWATM204 (GPC3-targeted CAR-T) Autologous CAR-T product targeting GPC3 (glypican-3) for hepatocellular carcinoma and solid tumors, based on Eureka's CAR constructs, in a Phase I investigator-initiated trial in China.
  • JWATM214 CAR-T product for solid tumors developed using Lyell technology, in preclinical and early clinical development.
  • Relma-cel for Systemic Lupus Erythematosus (SLE) CD19 CAR-T therapy (relmacabtagene autoleucel) being developed for autoimmune indications including SLE and lupus nephritis; Phase 1 data showed a 100% SRI-4 response rate.
  • Relma-cel for Systemic Sclerosis (SSc) CD19 CAR-T therapy (relmacabtagene autoleucel) for progressive diffuse cutaneous systemic sclerosis; Phase 1 trial demonstrated deep B-cell depletion and was presented at SSWC 2026 as a Late-Breaking abstract.

Quantifiable outcome

  • 100% SRI-4 response rate in SLE Phase 1 trial (12/12 patients)
  • +3 more outcomes

Companies that use JW Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

JW Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

JW Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • ImugenecoreStrategic or Co-development Partner · 28 November 2025Collaboration to evaluate combination of Imugene's CF33-CD19 oncolytic virus (onCARlytics) with JW's Carteyva CD19 CAR-T therapy for refractory solid tumors. Includes preclinical studies and Phase 1 trial in China, developing novel 'mark and kill' treatment strategy.
  • Regeneron PharmaceuticalscoreStrategic or Co-development Partner · 30 October 2025Expanded strategic collaboration for TCR-T cell therapy development. JW Therapeutics receives up to USD 50 million in milestone payments for MAGE-A4 product development. Regeneron grants non-exclusive global license to JW Therapeutics' Drug Product Process and option for Lentiviral Vector Manufacturing Process. JW Therapeutics retains Greater China development and commercialization rights.
  • Regeneron Pharmaceuticals (via 2seventy Bio acquisition)coreStrategic or Co-development Partner · 30 October 2025Strategic alliance for MAGE-A4 TCR.CTBR12 (JWTCR001) development in China, Hong Kong, and Macau. JWTCR001 uses proprietary CTBR12 switch receptor technology to convert TGF-beta suppression into activation signal for enhanced antitumor activity in solid tumors.
  • Juno Therapeutics (Bristol Myers Squibb)coreOEM/ Whitelabel/ Licensing Partner · 14 April 2025sLVV (self-developed lentiviral vector) manufacturing technology licensing agreement. JW Therapeutics grants Juno non-exclusive license to JW sLVV manufacturing process for CAR-T production. Total consideration up to USD 10 million. Juno is BMS's CAR-T subsidiary and JW Therapeutics' largest shareholder.
  • WuXi AppTec (药明康德)coreStrategic or Co-development Partner · 1 January 2016JW Therapeutics was co-founded in 2016 by WuXi AppTec and Juno Therapeutics, combining global cell therapy expertise with Chinese pharmaceutical development and manufacturing capabilities.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

JW Therapeutics competitors and assessment

Company assessment

Emerging players

  • Cellectis: Clinical-stage gene and cell therapy company developing allogeneic CAR-T and TCR-T platforms; competes in JW's solid tumor and hematologic cell therapy development space across multiple modalities.
  • Allogene Therapeutics: US-listed allogeneic CAR-T developer whose off-the-shelf approach could disrupt the autologous CAR-T economics on which JW's Carteyva depends; competitor in the broader hematologic cell therapy market.
  • Eureka Therapeutics: US/CN clinical-stage biotech developing solid-tumor CAR-T constructs (including GPC3 targeting) - JW's JWATM204 program is based on Eureka's CAR constructs, making Eureka a technology licensor and direct pipeline peer.

Direct peers

  • Carsgen Therapeutics: Hong Kong-listed Chinese CAR-T developer of zevorcabtagene autoleucel (zev-cel, CT041), approved for multiple myeloma and operating in CAR-T cell therapy with overlapping hematologic malignancy indications.
  • Legend Biotech: Develops Carvykti, a BCMA-directed CAR-T co-developed with Johnson & Johnson for multiple myeloma - a direct BCMA-targeting CAR-T peer overlapping with JW's JWCAR129 pipeline asset.
  • Fosun Kite Biotechnology: Chinese JV between Fosun Pharma and Kite (Gilead) that localizes and commercializes Yescarta CAR-T therapy in China for B-cell NHL - directly competes with Carteyva in the same approved indications and hospital channel.
  • Gracell Biotechnologies: Chinese allogeneic CAR-T developer acquired by AstraZeneca, focused on B-cell malignancies and autoimmune - directly competes in next-generation cell therapy formats targeting the same Chinese patient population.

Broad incumbents

  • Bristol Myers Squibb: Global CAR-T leader through its Juno Therapeutics subsidiary (Brexucabtagene Autoleucel / Breyanzi / Abecma) and JW Therapeutics' largest shareholder and technology-licensing partner - defines the competitive and governance landscape for JW.
  • Novartis: Develops and commercializes Kymriah, the first FDA-approved CAR-T therapy; a global incumbent in the same CAR-T modality that JW Therapeutics targets, providing global competitive and regulatory benchmarks.
  • Gilead Sciences (Kite): Markets Yescarta and Tecartus CAR-T therapies globally via its Kite subsidiary, including in China through the Fosun Kite JV - establishes the competitive CAR-T benchmark JW must beat on cost, manufacturing, and indication breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

JW Therapeutics social profiles

Digital presence

JW Therapeutics compliance and trust

Trust signal

Compliance4 records

JW Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JW Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

JW Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JW Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JW Therapeutics

What does JW Therapeutics do?

JW Therapeutics develops, manufactures, and commercializes autologous CAR-T cell immunotherapy products. Its flagship product Carteyva (relmacabtagene autoleucel injection) is approved in China for three non-Hodgkin lymphoma indications (r/r LBCL, r/r FL, r/r MCL) and priced at CNY 999,000 to CNY 1.3 million per infusion. The company also licenses its proprietary manufacturing processes (including self-developed lentiviral vector technology) to global partners such as Juno Therapeutics/BMS.

Is JW Therapeutics a public or private company?

JW Therapeutics is a public company. It is classified as public and is currently operating.

When was JW Therapeutics founded?

JW Therapeutics was founded in 2016. It employs 101 to 250 people.

Where is JW Therapeutics based?

JW Therapeutics is headquartered in Shanghai, China, in the Asia region.

How does JW Therapeutics make money?

Two revenue lines are on record. CAR-T Product Sales (Carteyva/Bienaida) is the primary driver. The others are technology Licensing and Milestone Payments.

Who are JW Therapeutics's main competitors?

Emerging players on record are Cellectis, Allogene Therapeutics and Eureka Therapeutics. Direct peers are Carsgen Therapeutics, Legend Biotech, Fosun Kite Biotechnology and Gracell Biotechnologies. Broad incumbents are Bristol Myers Squibb, Novartis and Gilead Sciences (Kite).

Does JW Therapeutics have an API?

No public API is recorded for JW Therapeutics.

What industry is JW Therapeutics in?

JW Therapeutics's product category is Cell Immunotherapy (CAR-T). Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCarteyva Registered Included in China's 2026 National Reimbursement Drug ListJW Therapeutics announced that its CAR-T therapy Carteyva Registered was included in China's 2026 National Reimbursement Drug List, effective January 1, 2027. It is the only CAR-T therapy in the list, covering three lymphoma indications. The company expects reimbursement to reduce out-of-pocket costs for eligible patients.FinancialContent Business PageCarteyva® Included in China’s 2026 National Reimbursement Drug ListJW Therapeutics announced that Carteyva, its CAR-T therapy, was included in China's 2026 National Reimbursement Drug List, the only CAR-T therapy in that edition. The listing takes effect January 1, 2027, covering three lymphoma indications. The company expects reimbursement to reduce out-of-pocket costs for eligible patients.Business & FinancialCarteyva® Included In China's 2026 National Reimbursement Drug ListCarteyva was added to China's 2026 national reimbursement drug list, expected to lower out-of-pocket costs for eligible patients. The drug is approved for three lymphoma indications and is the only CAR-T therapy listed. JW Therapeutics plans to continue manufacturing improvements to support potential demand increases.Dealroom.coJW Therapeutics raises $20.4M to fund CAR-T pipeline | Dealroom NewsJW Therapeutics agreed to raise $19.3M via a post-IPO share subscription, issuing 61.1855 million new shares at $0.32 each to China Hongqiao Holdings and Novo Vista. The funds will support its CAR-T pipeline, with 40% for in-vivo candidates and 30% for autologous ones. The raise comes as its lead therapy Carteyva becomes the first CAR-T treatment added to China's national reimbursement list, effective January 2027.YicaiglobalJW Therapeutics’ CAR-T Drug Enters China’s Reimbursement List With 78% Price Cut; Can Still Be Profitable, CEO SaysJW Therapeutics' CAR-T drug Carteyva was added to China's 2026 National Reimbursement Drug List, with the reimbursement price cut by 78% to about CNY288,600 per dose. CEO Tian Feng said the price is sufficient for sustainable operations, and the company expects to cut manufacturing costs to reach profitability. Demand is expected to rise, potentially adding 11,000 patients annually.The future of tradingJW Therapeutics Agrees to HKD 160 Million Private Share PlacementJW Cayman Therapeutics agreed on November 15, 2026, to raise HK$160 million through a share subscription by two institutional investors. The placement comprises 61,185,465 new shares at HK$2.615 each, a 2.97% discount to the last closing price. Estimated net proceeds of HK$158.8 million will primarily fund CAR-T research, technology platforms, and manufacturing capabilities.The future of tradingJW Therapeutics Expects Carteyva Unit Manufacturing Costs to Fall More Than 65%JW Therapeutics expects Carteyva unit manufacturing costs to fall more than 65% after cost optimization, supporting positive unit economics. The drug's reimbursement price under China's National Reimbursement Drug List is RMB 288,600, effective January 1, 2027. Covered indications represent about 11,000 new eligible patients annually.MoomooHong Kong Stock Market Movements | JW Therapeutics-B (02126) Rises Over 5%; Plans to Transfer Equity Rights of Liver Cancer TCR-T Project to Ureka Hong KongJW Therapeutics shares rose over 5% to HK$2.69 on November 9, 2026, after the company announced a license and assignment agreement with Eureka Hong Kong. The deal includes a US$10 million upfront payment and potential commercial milestone payments up to US$100 million.MoomooJW Therapeutics-B (02126) intends to assign its equity interests in the hepatocellular carcinoma TCR-T project to Eureka Hong Kong.JW Therapeutics-B and JWS entered a license and assignment agreement with Eureka Hong Kong on November 9, 2026, transferring rights to hepatocellular carcinoma TCR-T products. Eureka will pay a $10 million upfront payment, with commercial milestones not exceeding $100 million. The company will prioritize R&D on other projects like JWCAR201 and JWCAR239.